SELLAS Life Sciences Group, Inc. (SLS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 0.00 USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $0.00 | (m) |
| 2025-06-30 | (m) | (m) | $0.00 | (m) |
| 2023-12-31 | (m) | $0.00 | $0.00 | (m) |
| 2023-09-30 | (m) | $0.00 | $0.00 | (m) |
| 2023-06-30 | (m) | $0.00 | $0.00 | (m) |
| 2023-03-31 | (m) | $0.00 | $0.00 | (m) |
| 2022-12-31 | (m) | $1.00M | $100.00K | (m) |
| 2022-09-30 | (m) | $1.00M | $100.00K | (m) |
| 2022-06-30 | (m) | $1.00M | $100.00K | (m) |
| 2022-03-31 | (m) | $2.90M | $200.00K | (m) |
| 2021-12-31 | (m) | $7.60M | $200.00K | (m) |
| 2021-09-30 | (m) | $9.50M | (m) | (m) |
| 2021-06-30 | (m) | $9.50M | (m) | (m) |
| 2021-03-31 | (m) | $7.60M | (m) | (m) |
| 2020-12-31 | (m) | $1.90M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $0.00 | (m) | (m) |
| 2015-06-30 | (m) | $10.95M | (m) | (m) |
| 2015-03-31 | (m) | $9.90M | (m) | (m) |
| 2014-12-31 | (m) | $9.32M | (m) | (m) |
| 2014-09-30 | (m) | $7.44M | (m) | (m) |
| 2014-06-30 | (m) | $6.99M | (m) | (m) |
| 2014-03-31 | (m) | $4.66M | (m) | (m) |
| 2013-12-31 | $1.84M | $2.49M | (m) | 73.82% |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | $0.00 | $0.00 | (m) | (m) |
| 2013-03-31 | $0.00 | $0.00 | (m) | (m) |
| 2012-12-31 | $0.00 | $0.00 | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |